Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glycopeptide - ProtoKinetix

Next Previous
Drug Profile

Glycopeptide - ProtoKinetix

Alternative Names: AAGP® molecules

Latest Information Update: 26 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Institut National des Sciences Appliquees de Rouen; ProtoKinetix
  • Developer Imaginative Research Associates; ProtoKinetix; ProtoKinetix - Imaginative Research Associates (JV); University of British Columbia
  • Class Anti-inflammatories; Eye disorder therapies; Glycopeptides; Glycoproteins; Skin disorder therapies; Small molecules
  • Mechanism of Action Antioxidants; Free radical scavengers; Selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Transplant rejection
  • Preclinical Ocular inflammation; Renal transplant rejection
  • Research Radiation-induced skin damage; Skin disorders
  • No development reported Dry eyes; Inflammation; Macular degeneration

Most Recent Events

  • 26 Jul 2024 Phase-I clinical trials in Transplant rejection (unspecified route), prior to July 2024 (ProtoKinetix pipeline, July 2024)
  • 25 Jul 2024 Glycopeptide is still in preclinical trials for Ocular inflammation in Canada (Unspecified), prior to July 2024 (ProtoKinetix pipeline, July 2024)
  • 25 Jul 2024 Glycopeptide is still in preclinical trials for Skin disorders in Canada (Unspecified), prior to July 2024 (ProtoKinetix pipeline, July 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top